A Phase I, Open-Label, Multi-Center, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of ATG-018 (ATR Inhibitor) Treatment in Patients With Advanced Solid Tumors and Hematological Malignancies

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 24 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATG 018 (Primary)
Indications Diffuse large B cell lymphoma; Haematological malignancies; Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions
Acronyms ATRIUM
Sponsors Antengene Corporation

Most Recent Events

18 Jul 2024 Status changed from recruiting to discontinued. ( Lack of efficacy of study compound)
19 Apr 2024 Planned primary completion date changed from 31 Mar 2024 to 30 Jun 2024.
16 Aug 2022 According to an Antengene Corporation media release, the first patient has been dosed in this trial

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight